Market Closed -
Xetra
16:36:18 26/04/2024 BST
|
5-day change
|
1st Jan Change
|
2.97
EUR
|
-1.98%
|
|
-1.00%
|
-20.59%
|
Fiscal Period: November |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Capitalization
1 |
62.23
|
161.5
|
177
|
266.5
|
128.6
|
138.4
|
-
|
Enterprise Value (EV)
1 |
52.35
|
156.7
|
171
|
266.5
|
128.6
|
138.4
|
138.4
|
P/E ratio
|
-6.14
x
|
-8.52
x
|
-6.48
x
|
-10.8
x
|
-6.27
x
|
-9.9
x
|
-22.8
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
7.81
x
|
16.9
x
|
76.5
x
|
13.4
x
|
7.66
x
|
12
x
|
9.23
x
|
EV / Revenue
|
7.81
x
|
16.9
x
|
76.5
x
|
13.4
x
|
7.66
x
|
12
x
|
9.23
x
|
EV / EBITDA
|
-6.48
x
|
-9.2
x
|
-7.13
x
|
-16.2
x
|
-6.33
x
|
-6.26
x
|
-12.8
x
|
EV / FCF
|
-6,579,197
x
|
-8,385,943
x
|
-6,355,429
x
|
-
|
-
|
-
|
-
|
FCF Yield
|
-0%
|
-0%
|
-0%
|
-
|
-
|
-
|
-
|
Price to Book
|
3.83
x
|
12.5
x
|
26.4
x
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
28,158
|
31,062
|
34,173
|
46,584
|
46,600
|
46,605
|
-
|
Reference price
2 |
2.210
|
5.200
|
5.180
|
5.720
|
2.760
|
2.970
|
2.970
|
Announcement Date
|
19/03/20
|
25/03/21
|
24/03/22
|
05/03/23
|
25/03/24
|
-
|
-
|
Fiscal Period: November |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Net sales
1 |
7.964
|
9.576
|
2.314
|
19.86
|
16.8
|
11.5
|
15
|
EBITDA
1 |
-9.597
|
-17.55
|
-24.83
|
-16.42
|
-20.33
|
-22.1
|
-10.8
|
EBIT
1 |
-10.14
|
-18.28
|
-25.63
|
-17.18
|
-21.21
|
-22.6
|
-11.6
|
Operating Margin
|
-127.36%
|
-190.95%
|
-1,107.81%
|
-86.51%
|
-126.24%
|
-196.52%
|
-77.33%
|
Earnings before Tax (EBT)
|
-10.14
|
-18.28
|
-26.14
|
-17.79
|
-20.35
|
-
|
-
|
Net income
|
-10.15
|
-18.28
|
-26.14
|
-19.7
|
-20.35
|
-
|
-
|
Net margin
|
-127.43%
|
-190.95%
|
-1,129.76%
|
-99.2%
|
-121.1%
|
-
|
-
|
EPS
2 |
-0.3600
|
-0.6100
|
-0.8000
|
-0.5300
|
-0.4400
|
-0.3000
|
-0.1300
|
Free Cash Flow
|
-9.458
|
-19.26
|
-27.85
|
-
|
-
|
-
|
-
|
FCF margin
|
-118.77%
|
-201.14%
|
-1,203.84%
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
19/03/20
|
25/03/21
|
24/03/22
|
05/03/23
|
25/03/24
|
-
|
-
|
Fiscal Period: November |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
9.88
|
4.78
|
5.97
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-9.46
|
-19.3
|
-27.9
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-48.1%
|
-125%
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-37.5%
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
|
27.09
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
0.5800
|
0.4100
|
0.2000
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
|
0.9
|
1.37
|
1.24
|
-
|
-
|
-
|
-
|
Capex / Sales
|
11.32%
|
14.29%
|
53.69%
|
-
|
-
|
-
|
-
|
Announcement Date
|
19/03/20
|
25/03/21
|
24/03/22
|
05/03/23
|
25/03/24
|
-
|
-
|
Last Close Price
2.97
EUR Average target price
11.3
EUR Spread / Average Target +280.47% Consensus |
1st Jan change
|
Capi.
|
---|
| -20.59% | 148M | | -2.31% | 103B | | +0.56% | 95.28B | | +1.69% | 22.15B | | -17.37% | 21.02B | | -9.30% | 18.15B | | -41.01% | 16.74B | | -14.85% | 16.05B | | +3.21% | 13.68B | | +33.54% | 12.17B |
Bio Therapeutic Drugs
|